PT - JOURNAL ARTICLE AU - TAKEHISA HEBISHIMA AU - YASUNOBU MATSUMOTO AU - GEN WATANABE AU - GEN-ICHIRO SOMA AU - CHIE KOHCHI AU - KAZUYOSHI TAYA AU - YOSHIHIRO HAYASHI AU - YOSHIKAZU HIROTA TI - Recovery from Immunosuppression-related Disorders in Humans and Animals by IP-PA1, An Edible Lipopolysaccharide DP - 2010 Aug 01 TA - Anticancer Research PG - 3113--3118 VI - 30 IP - 8 4099 - http://ar.iiarjournals.org/content/30/8/3113.short 4100 - http://ar.iiarjournals.org/content/30/8/3113.full SO - Anticancer Res2010 Aug 01; 30 AB - Immunopotentiator from Pantoea agglomerans 1 (IP-PA1), an edible lipopolysaccharide (LPS) derived from symbiotic bacteria in crops, is a promising immunomodulator. It activates macrophages and protects from chemotherapeutic agent-induced growth inhibition in macrophages in vitro. We showed the immune-recovery effects of IP-PA1 in a chicken model of dexamethasone-induced stress in which IP-PA1 inhibited thymic and bursal atrophy and improved antibody production in response to vaccination. Furthermore, we showed IP-PA1 improved survival of melanoma-bearing, doxorubicin-treated mice, although not directly affecting the proliferation of melanoma cells, dominantly through the improvement of host antitumor immunity. These results suggest that IP-PA1 could have other possible applications in the treatment of various immunosuppression-related disorders in humans and animals.